UCB transfers back to Recordati the rights for the sale of Corifeo® (Lercanidipine) in Germany
Brussels (Belgium), 24 April 2006 - UCB announces that it has reached an agreement with Recordati to transfer back the sales and marketing rights in Germany of Corifeo®, an antihypertensive calcium channel blocker, for a payment to UCB of 10 million euros.
"This transaction is another step taken by UCB in its strategy to focus on innovation for specialists particularly in the fields of the central nervous system, inflammation (including allergy) and oncology," declared Bill Robinson, Executive Vice President Global Operations of UCB.
UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing over 8,500 people in over 40 countries, UCB achieved revenues of EUR 2.3 billion in 2005. UCB is listed on the Euronext Brussels Exchange with a market capitalization of approximately EUR 6.0 billion. Worldwide headquarters are located in Brussels, Belgium.
Inquiries, please contact:
Corporate Communications and Investor Relations
Stay up-to-date on the latest news and information from UCB